News
PolyPid Provides Corporate Update and Reports Third Quarter 2026 Financial Results
D-PLEX NDA Under FDA Priority Review with PDUFA Goal Date of November 28, 2026; U.S. Commercial Launch Preparations Ongoing Expanding D-PLEX Globally: MAA Submitted and Validated by the EMA and European Commercialization Rights to D-PLEX Regained "PolyPid 2030" Growth...
PolyPid to Report Third Quarter 2026 Financial Results and Operational Highlights on November 11, 2026
PETACH TIKVA, Israel, Oct. 29, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today...
PolyPid Unveils Expanded Pipeline Strategy, Introducing PD01B, a New Kynatrix™ Based Product Candidate for the Treatment of Diabetic Foot Infections
Company to host virtual Investor Day today at 11:30 AM ET, featuring key opinion leader Warren S. Joseph, DPM, FIDSA All scheduled FDA interactions on track and aligned with D-PLEX November 28, 2026 PDUFA goal date PolyPid introduces PD01B, a new product candidate...
PolyPid to Present D-PLEX Microbiology Data at IDWeek 2026
Analysis demonstrates a lower bacterial burden in breakthrough surgical-site infections, with similar proportions of multidrug-resistant organisms between treatment groupsPETACH TIKVA, Israel, Oct. 21, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or...
PolyPid to Host Virtual Investor Day on Wednesday, October 28, 2026
Management to outline 'PolyPid 2030', the Company's long-term vision and pipeline strategy Event to feature Warren S. Joseph, DPM, FIDSA, a nationally recognized specialist in lower extremity infectious diseases Petach Tikva, Israel, Oct. 15, 2026 (GLOBE NEWSWIRE) --...
European Medicines Agency Validates PolyPid’s Marketing Authorization Application for D-PLEX
PolyPid Submitted Marketing Authorization Application to European Medicines Agency for D-PLEX Last month Validation confirms that the application is complete and EMA initiates formal review of D-PLEX D-PLEX NDA concurrently under FDA Priority Review with November 28,...
PolyPid Regains European Commercialization Rights for D-PLEX , Expanding Global Commercialization Opportunities
PETACH TIKVA, Israel, Oct. 01, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today...
PolyPid Announces Participation in Upcoming Fall Investor Conferences
PETACH TIKVA, Israel, Sept. 15, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today...
PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results
FDA Accepted D-PLEX NDA with Priority Review; PDUFA Goal Date of November 28, 2026, Approximately One Quarter Ahead of Previously Communicated Guidance Exclusive U.S. and Canada Commercialization Partnership with Azurity Pharmaceuticals; $30 Million in Upfront and...
PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026
PETACH TIKVA, Israel, July 30, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today...
